Mitobulin is an injectable chemotherapy medication containing Eribulin Mesylate, a synthetic analog of the marine natural product halichondrin B. It is administered intravenously and is primarily used in the treatment of certain types of cancer. Eribulin is known for its unique mechanism of action and is considered an important option in cancer chemotherapy.

Mechanism of Action

Eribulin exerts its anticancer effects by:

• Inhibiting microtubule dynamics: Eribulin binds to tubulin, inhibiting microtubule growth and preventing the formation of mitotic spindles, which are essential for cell division.

• Inducing mitotic arrest: By disrupting microtubule dynamics, Eribulin causes cells to arrest in mitosis, leading to cell death through apoptosis.

  Uses

  Mitobulin is indicated for:

  • Metastatic Breast Cancer: Particularly in patients who have previously received chemotherapy regimens, including anthracyclines and taxanes.

  • Liposarcoma: A type of cancer that arises from fat cells in soft tissue.

    Adverse Effects

    Common side effects of Mitobulin include:

    • Fatigue: A general feeling of tiredness or weakness.

    • Nausea and Vomiting: Gastrointestinal disturbances.

    • Hair Loss (Alopecia): Temporary hair thinning or loss.

    • Peripheral Neuropathy: Tingling, numbness, or pain in the hands and feet.

    • Anemia: Low red blood cell count leading to fatigue and weakness.